Schedule

Audio Recorded Topics

Sunday, July 1, 2018

The following topics will be recorded and made available to participants of the course by July 1, 2018. These recorded topics are included in your meeting registration at no additional charge.
Cancer-Releated Infectious Diseases
1.00 hours of CPE credit.
Anthony Perisonetti, Pharm.D., BCOP
Perisonetti

Speakers
  • Faculty: Anthony Perisonetti, Pharm.D., BCOP
    Clinical Pharmacist Specialist, Inpatient Hematology, University of Michigan Health System, Ann Arbor, Michigan

Learning Objectives
1. Design an appropriate patient‐specific management and monitoring plan to address potential infection‐related problems that may arise during or following cancer treatment based on the current guidelines for treating cancer-related infectious diseases.
2. Determine short‐ and long‐term treatment goals, including post-therapy, with a patient with a cancer-related infectious disease and his or her caregiver.
Thyroid
0.50 hours of CPE credit.
Christine M. Walko, Pharm.D., BCOP
Walko

Speakers
  • Faculty: Christine M. Walko, Pharm.D., BCOP
    Clinical Pharmacogenetics Scientist, Moffitt Cancer Center, Tampa, Florida
      View Biography

Learning Objectives
1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with thyroid cancer.
2. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with pharmacotherapy for thyroid cancer.
Upper Gastrointestinal and Hepatocellular Carcinomas
0.75 hours of CPE credit.
Andrea Landgraf Oholendt, Pharm.D., BCOP
Landgraf Oholendt

Speakers
  • Faculty: Andrea Landgraf Oholendt, Pharm.D., BCOP
    Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, Texas
      View Biography

Learning Objectives
1. Design an appropriate patient-specific treatment, management, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with esophageal, gastric, or hepatic malignancies.
2. Assess the impact of pharmacogenomics on the efficacy and toxicity of relevant anticancer agents used for gastrointestinal malignancies.
3. Devise and communicate appropriate plans for preventing, monitoring, and treating radiation recall and other complications of radiation therapy.
Pharmacogenomics in Oncology
0.50 hours of CPE credit.

Speakers
  • Faculty: Christine M. Walko, Pharm.D., BCOP
    Clinical Pharmacogenetics Scientist, Moffitt Cancer Center, Tampa, Florida
      View Biography

Learning Objectives
1. Identify appropriate considerations for genetic interpretation in both the germline and somatic settings utilizing next generation sequencing techniques.
2. Translate the results from somatic genetic testing into therapeutic recommendations based on prognostic and predictive information and patient characteristics.
3. Recognize the place in therapeutic decision making for companion diagnostic testing.
Hematopoietic Stem Cell Transplantation
1.25 hours of CPE credit.
Lauren Ice, Pharm.D.
Ice

Speakers
  • Faculty: Lauren Ice, Pharm.D.
    Clinical Pharmacist, Adult Blood and Marrow Transplant, Spectrum Health, Grand Rapids, Michigan
      View Biography

Learning Objectives
1. Design an appropriate patient‐specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients undergoing hematopoietic stem cell transplantation (HSCT
2. Debate the advantages and disadvantages of various methods of peripheral blood stem cell mobilization.
3. Discern dose‐limiting toxicities and appropriate strategies to prevent toxicity from chemotherapy agents employed in HSCT conditioning regimens, and differentiate between myeloablative, non‐myeloablative, and reduced-intensity HSCT conditioning regimens.
4. Create a plan for prevention and management of acute and chronic graft‐versus‐host disease (GVHD) using appropriate systemic and ancillary therapies.
5. Discuss short‐ and long‐term treatment goals, including post‐therapy and survivorship, with the patient undergoing HSCT and his or her caregiver
© 2018 American College of Clinical Pharmacy and American Society of Health‑System Pharmacists